Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Budget
- Internal Trade
- International Trade
- Defence
- Economic Development
- Regional Development
- Education
- Employment and Training
- Energy
- Environment
- Forestry
- Immigration
- Taxation and Finance
- Industry
- Infrastructure
- Financial Institutions
- Justice and Law Enforcement
- Government Procurement
- Fisheries
- Small Business
- Intellectual Property
- Constitutional Issues
- Consumer Issues
- Research and Development
- International Relations
- Health
- Science and Technology
- Sports
- Transportation
- Labour
Subject Matter Details
Politique ou Programme
- Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
- Guidance for Industry: Issuance of Health Professional Communications and Public Communications by Market Authorization Holders and Draft Guidance Document: Triggers for Issuance of Risk Communication Documents for
Marketed Health Products for Human Use with respect to communications from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs
- Health Canada International Memorandum of Understanding with respect to exchanging data and safety protocols
- Health Canada Post Notice of Compliance Change Guidance: Quality with respect to the categorization of a change and the recommended supporting data for any changes to the Quality information associated with a new drug
- Implementation of the National Pharmaceutical Strategy as it affects the industry
- Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
- Patent Act as it relates to changes to Canada's Access to Medicines Regime
- Patented Medicine Prices Review Board in respect of proposed Pricing Guidelines
- Progressive Licensing Framework with respect to its development and government consultations
- Science and Technology Strategy as it relates to new policies for the pharmaceutical industry
- Therapeutic Products Directorate's work as it relates the Guidance for Industry: Management of Drug Submissions with respect to the review and approval of submissions
Politique ou Programme, Proposition législative, Projet de loi ou résolution
- Food and Drugs Act as it relates to modernization
Politique ou Programme, Règlement
- Creation of pathways for Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors: Information and Submission Requirements for SEBs, regulations and intellectual property policies
Proposition législative, Projet de loi ou résolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Patent Act as it relates to further changes affecting patent term restoration
- User Fees Act with respect to cost recovery
Règlement
- Amendments to the Food and Drugs Act Regulations as it relates to further changes to data protection
- Data Protection Regulations with respect to its implementation and application to the Food and Drugs Act
- Patent Act as it relates to Patented Medicines (Notice of Compliance) Regulations and possible changes to modernize and Right of Appeal
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Foreign Affairs, Trade and Development Canada
-
Public Health Agency of Canada (PHAC)
-
Atlantic Canada Opportunities Agency (ACOA)
-
Federal Economic Development Agency for Southern Ontario (FedDev)
-
Canadian Space Agency (CSA)
-
Agriculture and Agri-Food Canada (AAFC)
-
Veterans Affairs Canada (VAC)
-
Privy Council Office (PCO)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Prime Minister's Office (PMO)
-
House of Commons
-
Citizenship and Immigration Canada
-
Office of the Information and Privacy Commissioner (OIPC)
-
Public Service Commission of Canada (PSC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Natural Sciences and Engineering Research Council (NSERC)
-
National Research Council (NRC)
-
National Defence (DND)
-
Members of the House of Commons
-
Western Economic Diversification Canada (WD)
-
Employment and Social Development Canada (ESDC)
-
Environment Canada
-
Finance Canada (FIN)
-
Royal Canadian Mounted Police (RCMP)
-
Industry Canada
-
Canadian Institutes of Health Research (CIHR)
-
Justice Canada (JC)
-
Canadian Transportation Agency (CTA)
-
Natural Resources Canada (NRCan)
-
Revenue Canada (RC)
-
Health Canada (HC)
-
Treasury Board Of Canada Secretariat (TBS)
-
Public Safety and Emergency Preparedness Canada (PSEPC)
-
Senate of Canada
-
Service Canada (ServCan)
-
Correctional Service of Canada (CSC)
-
Solicitor General Canada (SGC)
-
Statistics Canada (StatCan)
-
Transport Canada (TC)
-
Public Works and Government Services Canada
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
In-house Corporation Details
Description of activities
Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
Responsible officer name and position during the period of this registration
RONNIE MILLER,
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Government funding
End date of the last completed financial year:
2012-12-31
List of Government Funding
Government Institution
|
Funding Received in Last Financial Year
|
Funding Expected in Current Financial Year
|
Minister of Economic Development and Trade - Ontario
|
$0.00
|
Yes
|
In-house Corporation Contact Information
Address:
7070 Mississauga Road
Mississauga, ON L5N 5M8
Canada
Telephone number:
905-542-5555
Fax number:
905-542-5689
Parent Company Information
- F. Hoffmann-La Roche AG
-
Grenzacherstrasse 124
4070 Basle
Switzerland
Subsidiary Beneficiary Information
Hoffmann-La Roche Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- RONNIE MILLER,
PRESIDENT AND CHIEF EXECUTIVE OFFICER |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Lorenzo Biondi,
Vice President, Medical & Regulatory Affairs |
No public offices held
- Linda Jack,
Director Regulatory Affairs |
No public offices held
- Elizabeth Peace,
Manager, Government Relations and Health Policy |
Public offices held
- Ilona Torontali,
Vice President, Public Affairs |
No public offices held